Smartkarma Newswire

American Water Works Company, Inc. (AWK)

146.24 USD +3.18 (+2.22%) Volume: 1.6M

American Water Works Company, Inc.’s stock price is currently strong at 146.24 USD, marking an impressive trading session increase of +2.22% and a robust YTD growth of +17.47%, reflecting its solid performance in the market with a trading volume of 1.6M.

Latest developments on American Water Works Company, Inc.

American Water Works Company (AWK) made headlines today as they announced plans to invest $40-$42 billion in infrastructure across the U.S. over the next decade, focusing on water infrastructure improvements. This news comes after the resignation of board member Harris and the step down of director Harris. Despite this shakeup, Jefferies raised their stock target for American Water, setting it at $115, although still keeping it underperform. In addition, the president of West Virginia American Water addressed water infrastructure issues in the state, emphasizing the importance of continuing to provide safe, clean, and reliable water service. American Water also collaborated with the City of Camden to showcase ongoing water infrastructure improvements in the community, highlighting their commitment to delivering quality service.

American Water Works Company, Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma have published a bullish insight on American Water Works Co. The research report, titled “American Water Works: Infrastructure Investment & Rate Base Growth to Sustain The Growth Trajectory!”, highlights the company’s recent financial and operational performance in 2024. American Water reported earnings per share (EPS) of $5.39, showing an 8% growth due to favorable weather conditions and strategic investments. The company invested $3 billion in capital initiatives and successfully secured rate case agreements in multiple jurisdictions.

A look at American Water Works Company, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, American Water Works Co has a mixed long-term outlook. While the company scores high on momentum, indicating strong performance in the near future, it falls short in terms of value and growth. With a moderate score for dividends and resilience, the company shows stability but may lack significant growth potential in the long run.

American Water Works Co, Inc. is a leading provider of water services in the United States and Canada. The company primarily operates regulated utilities that supply water and wastewater services to a wide range of customers. Despite its solid track record in the industry, the Smartkarma Smart Scores suggest that American Water Works Co may face challenges in achieving substantial value and growth over the long term.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

PPL Corporation (PPL)

35.71 USD +0.73 (+2.09%) Volume: 10.03M

PPL Corporation’s stock price climbs to 35.71 USD, registering a positive trading session with a 2.09% increase and a significant trading volume of 10.03M. Boosted by a year-to-date percentage change of +10.01%, PPL’s strong performance underlines its growing market potential.

Latest developments on PPL Corporation

Today, PPL Corp’s stock price reached a 52-week high of $35.91, soaring amidst key events leading up to this significant movement. Corebridge Financial Inc. recently purchased 86,227 shares of PPL Co. (NYSE:PPL), indicating a growing interest in the company. Additionally, Zions Bancorporation N.A. disclosed holdings of $4.31 million in PPL Co., further boosting investor confidence. TD Private Client Wealth LLC also increased their position in PPL Co., contributing to the positive momentum. Aviso Wealth Management’s acquisition of 7,896 shares of PPL Co. further solidifies the company’s position in the market, leading to the rise in stock price today.

PPL Corporation on Smartkarma

Analysts at Baptista Research on Smartkarma have been bullish on Ppl Corp, highlighting the company’s focus on a dividend growth strategy for sustainable business growth. In their research reports, they discussed PPL Corporation’s recent financial results for the fourth quarter and full year of 2024. Despite mild weather affecting earnings, the company reported an improvement in ongoing earnings per share (EPS) compared to the previous year, aligning with initial guidance.

Furthermore, Baptista Research analysts also pointed out PPL Corporation’s successful integration of Rhode Island energy and other major drivers in their coverage. They noted a mixed performance in the company’s third-quarter 2024 financial results, with GAAP earnings slightly down from the previous year. Adjusted for special items, earnings from ongoing operations showed a decrease compared to the same quarter in 2023. Overall, the analysts remain optimistic about Ppl Corp‘s strategic planning and operational initiatives for future growth.

A look at PPL Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Looking at the Smartkarma Smart Scores for Ppl Corp, the company seems to have a positive long-term outlook. With high scores in Growth and Resilience, Ppl Corp appears to be well-positioned for future success. The company’s focus on value and dividends, coupled with strong momentum, further solidifies its standing in the market. As an energy and utility holding company, Ppl Corp‘s diverse operations in electricity generation and energy marketing give it a competitive edge in the industry.

Ppl Corp‘s Smartkarma Smart Scores reflect a company that is on a path towards continued growth and stability. With a strong emphasis on value, dividends, and resilience, Ppl Corp is well-equipped to weather any market fluctuations. The company’s momentum score indicates a positive trajectory for future performance. As Ppl Corp continues to expand its presence in the energy sector, its strategic positioning in key regions like the northeastern and western United States will likely drive further success in the coming years.

### PPL Corporation is an energy and utility holding company. The Company, through its subsidiaries, generates electricity from power plants in the northeastern and western United States, and markets wholesale and retail energy primarily in the northeastern and western portions of the United States, and delivers electricity in Pennsylvania and the United Kingdom. ###

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Bristol-Myers Squibb Company (BMY)

60.02 USD +1.12 (+1.90%) Volume: 10.79M

Bristol-Myers Squibb Company’s stock price is currently standing at 60.02 USD, showing a positive trading session with a 1.90% increase and a trading volume of 10.79M. With a year-to-date percentage change of +6.12%, BMY continues to demonstrate solid performance in the market.

Latest developments on Bristol-Myers Squibb Company

Recent events have influenced Bristol-Myers Squibb’s stock price movement today. The company received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for their neoadjuvant Opdivo and chemotherapy regimen. Additionally, Bristol-Myers CEO Christopher Boerner was awarded $19 million after a challenging year. The positive CHMP opinion for Opdivo in multiple solid tumors and the approval recommendation from the European Medicines Agency panel further boosted investor interest in the company. With a focus on AI innovation and transformative patient care, Bristol Myers Squibb continues to make strides in the healthcare industry despite a slight 3% share price dip.

A look at Bristol-Myers Squibb Company Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Bristol-Myers Squibb has a mixed long-term outlook. While the company scores high in Dividend and Momentum, indicating strong performance in these areas, it falls short in Value, Growth, and Resilience. This suggests that investors may need to carefully consider the company’s financial health and growth potential before making investment decisions.

Bristol-Myers Squibb Company is a global biopharmaceutical company that focuses on developing and selling pharmaceutical and nutritional products. With a strong emphasis on addressing various health issues such as cancer, heart disease, HIV and AIDS, and diabetes, the company has a diverse portfolio of products and experimental therapies. Despite some areas of concern in the Smartkarma Smart Scores, Bristol-Myers Squibb remains a key player in the healthcare industry with a focus on improving patient outcomes and advancing medical research.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Merck & Co., Inc. (MRK)

89.23 USD +1.63 (+1.86%) Volume: 12.39M

Merck & Co., Inc.’s stock price shows a promising surge at 89.23 USD, witnessing a positive leap of +1.86% in the latest trading session with a voluminous trade of 12.39M, despite experiencing a downtrend YTD at -10.30%, suggesting a potential rebound for MRK investors.

Latest developments on Merck & Co., Inc.

Merck & Co has been making strategic moves in the pharmaceutical industry, including plans to launch a US subcutaneous version of Keytruda on October 1. The company has laid out data for the subcutaneous Keytruda in lung cancer, amidst a patent dispute with Halozyme. Merck’s stock price has been volatile, with looming patent expiries for key drugs impacting its longer-term outlook. The FDA is set to make a decision on Merck’s subcutaneous Keytruda in September, while positive phase III data has given the company a potential boost. Merck has also secured marketing rights for cancer drugs and signed a $2 billion licensing deal for a heart disease drug. With various developments in the pipeline, investors are closely watching Merck’s stock movements.

Merck & Co., Inc. on Smartkarma

Analysts on Smartkarma are closely monitoring Merck & Co as the company’s financial performance reveals a mix of strengths and challenges. According to Baptista Research, Merck & Co‘s revenue increased by 7% to $15.6 billion in the fourth quarter of 2024, driven by strong performance in oncology and Animal Health segments. Despite facing headwinds with products like GARDASIL, the company’s innovative products like KEYTRUDA continue to drive demand.

Baptista Research also highlights Merck & Co‘s strategic advances in expanding its oncology portfolio through developments and partnerships related to KEYTRUDA. The company demonstrated a 4% revenue growth in the third quarter, with a strong global uptake of KEYTRUDA and successful product launches contributing to its performance. Analysts are evaluating various factors that could impact the company’s stock price in the near future, including conducting an independent valuation using a Discounted Cash Flow methodology.

A look at Merck & Co., Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Merck & Co has a solid outlook when it comes to dividends, scoring a 5 on the Smartkarma Smart Scores system. This indicates that the company is strong in terms of providing returns to its shareholders through regular dividend payments. Additionally, the company also shows good momentum with a score of 4, suggesting that it is performing well in the market and has positive growth potential in the near future.

However, Merck & Co scores lower on resilience with a 2, indicating that it may face some challenges in maintaining stability during tough economic times. Its value and growth scores are both at a moderate level of 3, showing that the company is fairly valued and has average growth prospects. Overall, Merck & Co is a global health care company with diverse operations in pharmaceuticals, animal health, and consumer care, positioning it well for long-term success in the industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Biggest stock gainers today in S&P 500

Biggest stock losers today in S&P 500

What is Smartkarma SmartScore?

It is a compound score for a Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores (Value, Dividend, Growth, Resilience, Momentum scores) computed by Smartkarma.

The best stock screener – Smartkarma SmartScore Screener

Smartkarma’s stock screener, Smartkarma SmartScore Screener, allows you to easily discover undervalued gems, high dividend stocks, and high growth stocks, across multiple countries and sectors.

Explore the Smartkarma SmartScore Screener now.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma